Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.68 |
| ▸ | CCND1 | P24385 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17822342 | 0.83 | CDK4 (0.76) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL29379363 | 0.83 | CDK4 (0.76) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL11366447 | 0.81 | CDK4 (1.00) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL945970 | 0.79 | CDK4 (0.71) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL1629560 | 0.77 | CDK4 (0.68) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL13227451 | 0.77 | CDK4 (0.68) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL32678601 | 0.77 | CDK4 (0.68) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL1616222 | 0.77 | CDK4 (0.68) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL315923 | 0.77 | CDK4 (0.68) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL32678603 | 0.77 | CDK4 (0.68) | CDK4CCND1KMT2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040783-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2721011-B1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | UNIV EMORY (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20170081314-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| US-9518044-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20140179750-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2721011-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | Emory University (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012177618-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2012-12-27 | — | — | WO | disclosed |
| US-8252944-B2 | Process for preparing heteroaromatic ring compound having N-Rf group | DAIKIN INDUSTRIES, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20120116097-A1 | PROCESS FOR PREPARING HETEROAROMATIC RING COMPOUND HAVING N-Rf GROUP | DAIKIN INDUSTRIES, LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040783-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGES | CDK4 1290/4885CCND1 3954/4885KMT2A 2359/4885 |
| US-20170081314-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | PTGER2, PTGES2, PTGES | CDK4 1290/4885CCND1 3954/4885KMT2A 2359/4885 |
| US-20140179750-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | PTGER2, PTGES2, PTGES | CDK4 1290/4885CCND1 3954/4885KMT2A 2359/4885 |
| US-20120116097-A1 | PROCESS FOR PREPARING HETEROAROMATIC RING COMPOUND HAVING N-Rf GROUP | CYP2F1, AFF1, AFF2 | CDK4 3291/4885CCND1 2044/4885KMT2A 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.